Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what plans they have to use artificial intelligence systems to support the diagnosis of prostate cancer, as recommended by the Lancet Commission in research published on 4 April.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to expand public awareness campaigns for prostate cancer, following the prediction by the Lancet Commission of a surge in cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to recent research conducted by the Lancet Commission, what steps they plan to take to address the projected surge in prostate cancer cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the Lancet Commission on prostate cancer, published 4 April 2024.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to prioritise research into variation of the prevalence of prostate cancer among different ethnic groups.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department welcomes the recently announced TRANSFORM trial which aims to save thousands of men each year by finding the best way to screen for prostate cancer across all ethnic groups. It will be spread across the United Kingdom, although final decisions on specific locations are yet to be taken. Men will be invited to participate via their general practices. This study, led by Prostate Cancer UK and supported by the Government among others, will also aim to address some of the inequalities that exist in prostate cancer diagnosis today by ensuring that one in ten of the trial participants will be black men, who are three times overrepresented compared to the population of men aged between 45 and 75 years old as based on 2021 census data.
More broadly, the National Institute for Health and Care Research (NIHR) funds research in response to proposals received from scientists and commissioned calls rather than allocating funding to specific disease areas. It welcomes funding applications for research into any aspect of human health, including prostate cancer. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality.
In addition, to raise awareness of prostate cancer in this group, Leicester’s Centre for BME Health has developed a toolkit in partnership with the NIHR with guidance on how to start conversations about prostate cancer and overcome barriers to diagnosis.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government when they intend to publish feedback to the Licensing of non-surgical cosmetic procedures consultation, which ran from 2 September to 28 October 2023.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
We are currently analysing the feedback received during the consultation, and intend to publish the Government’s response later in the spring.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of value lost to the economy through period inequity, as set out in the report, The State of Period Equity in the UK, published by In Kind Direct on 29 February.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
No formal assessment has been made. Menstrual health and gynaecological conditions are a priority in the Women’s Health Strategy for England. This strategy sets out our ambitions for improving information provision and tackling stigma surrounding topics such as periods and menstrual health, so society is better able to support women across their lives, including in schools and in workplaces. The statutory relationships, health, and sex education curriculum covers several areas of women’s health, including menstrual health. In July 2023 we launched a women’s health area on the National Health Service website, which brings together over 100 health topics, and includes a section on periods.
The Government is also committed to making period products more financially accessible, which will reduce barriers faced by women and girls in accessing education and work. The Period Product Scheme is available to girls and women in state-funded schools and colleges, providing a wide range of free period products, so that periods are not a barrier to education. 99% of secondary schools, 94% of post 16-year-old education organisations, and 75% of primary schools have used the scheme since it began in 2020. Free period products are also available for people in hospital and in custody. Since 1 January 2021, a zero rate of VAT has applied to sanitary products, and in January 2024 this was extended to include period pants.
Within the workplace, flexible working arrangements can allow individuals, including women suffering from menstrual problems, to work at a time, place, and during hours that support their needs. The Employment Relations (Flexible Working) Act makes changes to the right to request flexible working, to provide employees with better access to flexible working arrangements.
More widely, the Government continues to support people on lower incomes, including those who struggle to afford period products. We will spend approximately £124 billion on people of working age and children, through the welfare system in Great Britain, and the Government has provided support, totalling £96 billion, from 2022 onwards to help households with the cost of living. We are providing further support for 2024/2025, including uprating working age benefits by 6.7%, raising the National Living Wage, and extending the Household Support Fund in England for a further six months.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what estimate they have made, if any, of how many preventable hospitalisations have occurred as a result of medication shortages caused by Brexit.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom as well as the other countries around the world, and it can have a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
Whilst we can’t always prevent supply issues from occurring, we have a responsibility to manage and mitigate them, working in collaboration with the pharmaceutical industry, NHS England, the devolved administrations, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised.
Following the exit from the European Union (EU), the Department has worked collaboratively with industry to support trader readiness for the new border controls. While some suppliers experienced delays at the border associated with trader readiness, these issues were swiftly resolved with no sustained impacts on medical supplies, and the Department has no evidence of the EU Exit leading to sustained medicines shortages.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the findings in the Health Foundation report, Doing more for less?, published on 12 December, that (1) primary care network (PCN) funding is currently not sufficient to cover the additional challenges in areas of high deprivation, and (2) the current PCN contract focuses on addressing inequalities within PCNs, but not between PCNs.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Reducing health inequalities in health care is a priority for the National Health Service, and general practice and primary care networks (PCNs) have a major role to play in this.
Practices are paid for delivering essential and additional services based on the size of a practice’s registered list of patients. This funding accounts for patient sex, age, additional needs from a mortality and morbidity perspective, patient list turnover, care home residents and geographic location, including rurality and area costs.
PCNs also receive funding via the Network Contract Direct Enhanced Service, which sets out the requirements of PCNs. One of the core requirements of PCNs is to tackle neighbourhood health inequalities, as detailed in the Tackling Neighbourhood Health Inequalities Supplementary guidance, a copy of which is attached.
NHS England is undertaking a review of the Additional Roles Reimbursement Scheme, and outputs will inform the 2024/25 contract.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what estimate they have made of the economic costs of obesity in the UK, following the report Unhealthy Numbers: The Rising Cost of Obesity in the UK by Frontier Economics published on 21 November.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2021, the annual economic cost of obesity in the United Kingdom was estimated to be £58 billion; this includes costs to the National Health Service, losses to the economy and reductions in the quality of life of people. The Department has not made a specific estimate following the report. This report’s estimate includes the cost of overweight as well as obesity.